ABO and Alzheimer disease: Furthermore, imaging studies showed AD biomarkers at an early stage are associated with decreased gamma-aminobutyric acid (GABA) interneurons signaling rather than cholinergic or glutamatergic dysfunction, i.e., due to Aβ and, particularly, Aβ oligomers (AβO) pathology [23,37,38,39,40].